Prenosis

Name: Prenosis
Brand: Enosis Solutions

Transforming clinical diagnosis with predictive intelligence.

Est 2014|1 Ref Customers

LinkedIn 4K|Web traffic 2K|FTEs 44|HQ Chicago, Illinois, US

Published Aug 4, 2026

01Common complaints

- If procurement requires abundant third-party software reviews (G2/TrustRadius-style) before consideration - Prenosis currently has limited accessible review coverage on traditional software review platforms. - If an "all-in-one" enterprise deterioration monitoring platform is required - If the primary goal is enterprise-wide monitoring across multiple conditions, a broader surveillance platform may be a more appropriate primary purchase. - If the organization cannot support biomarker and data logistics - Where required lab biomarkers are not available with suitable turnaround time or cannot be operationalized, the clinical utility of the tool could be limited. - If the organization is tightly constrained to EHR-native workflows and cannot integrate a separate SaMD - EHR-native sepsis screening may be sufficient for some hospitals, particularly if evidence of incremental value from a separate SaMD is limited. - If security/compliance is a hard gate requiring public SOC 2 / ISO documentation before procurement - Public-facing materials reviewed did not clearly document SOC 2/ISO certifications; if this is a strict requirement, expect additional diligence and potential friction. - Current limitations acknowledged by the vendor - Prenosis positions Sepsis ImmunoScore® as complementary to alert systems and as a tool to be used with clinical assessment, indicating it is not intended to replace clinical judgment or existing protocols. - Roadmap and future expansion signals - 2026 funding announcements reference algorithm development/validation and expansion of Immunix into additional academic centers; timelines and specific product expansion details were not publicly published. - Scale limitations - Cloud delivery suggests technical scalability is feasible, but clinical integration scale is typically limited by hospital IT capacity and governance processes. - Security or compliance gaps - Public-facing materials did not clearly list SOC 2/ISO certifications, data residency options, or detailed enterprise security features. - Technical/API limitations - No specific public documentation of API capabilities or limitations was found; buyers should request API documentation and integration details during diligence.

Deal disqualifiers: what makes a POOR fit

Limited informatics resources for integration and monitoring
Low tolerance for workflow change
Inability to operationalize required biomarker testing or data capture with necessary turnaround times
Organizations that require extensive public third-party validation and broad peer reviews prior to piloting (public review footprint is limited)

02Why they buy

- Reported differentiators supported by accessible evidence (with caveats) - The product holds an FDA De Novo authorization for a sepsis risk assessment intended use, which is a notable regulatory distinction referenced in press coverage and vendor materials. - The solution is described as using a multi-parameter approach (biomarkers + clinical data) and presenting interpretability information in the user interface. - Distribution via the Roche navify Algorithm Suite is a reported channel that may affect availability in Roche-aligned laboratory and hospital customers. - Areas where competitors may have advantages - EHR-native models can have advantages related to deployment simplicity and embedded workflow tools. - Surveillance platforms can provide broader coverage for multiple deterioration conditions and centralized operational models. - Diagnostic assay-first competitors can offer different clinical utility (e.g., infection differentiation) that could align better with certain clinical protocols.

03Field reports

Review-platform reality check (important limitation)

- Traditional software review platforms have limited coverage for Prenosis as of the time of this report. - G2 lists Prenosis as a seller but shows minimal or no reviews and indicates there are insufficient reviews to provide buying insight. - TrustRadius- and Capterra-style review coverage for Prenosis as a product was not readily discoverable in accessible search results. - A Gartner Peer Insights product-specific review page for Prenosis was not identified in accessible sources; peer-insights coverage can also be constrained by category and access restrictions.

What exists instead (proxy evidence)

Public signals of user feedback are limited and generally consist of:
- Clinical and academic publications and preprints involving the tool (some with disclosed conflicts of interest)
- Press coverage and industry interviews
- Community discussion related to FDA authorization and category-level skepticism about sepsis models

Examples of community/social commentary (representative; not a direct product review base)

Reddit threads reacting to the FDA authorization news exist but do not provide the detailed implementation feedback typical of enterprise software reviews.
More broadly, clinicians and data science communities have expressed skepticism about sepsis prediction models (particularly EHR-vendor models), which raises expectations for transparent validation and workflow evidence for any sepsis AI product.

Reported reasons for interest in Prenosis (based on vendor positioning and press)

FDA De Novo authorization for the Sepsis ImmunoScore®
Vendor positioning that the product is intended to be used alongside clinical assessment rather than as an automated alerting-only tool
Use of biological markers and clinical parameters together, and presentation of interpretability features in product materials
Availability via Roche navify Algorithm Suite as a potential distribution channel

Reported reasons to delay or decline (based on observed gaps and market dynamics)

Limited public third-party review coverage makes peer validation less accessible
Integration and change management effort in acute care settings can be significant
Hospitals may have existing sepsis screening workflows and may require evidence of incremental value before adopting another tool

FDA De Novo authorization documents (regulatory evidence)

- FDA documentation indicates the Sepsis ImmunoScore® is intended to aid risk assessment for presence of or progression to sepsis within 24 hours and to be used with other clinical assessments. - FDA review documents describe post-market monitoring concepts and note methodological choices used to support authorization (for example, the use of computational determination of Sepsis‑3 criteria in monitoring rather than physician adjudication in some analyses). - Regulatory authorization indicates the device met marketing authorization requirements for its stated intended use, but authorization does not by itself establish cost savings or universal superiority across hospital contexts.

Clinical study signals (caution on independence/conflicts)

The peer‑reviewed and preprint literature contains studies reporting predictive performance and comparisons; some publications disclose Prenosis funding or authorship ties.
Buyers should request site‑by‑site performance, calibration methods, subgroup analyses (equity), and prospective impact studies demonstrating changes in clinical processes and patient outcomes in operational settings.

Vendor and partner materials

- A LabCorp article discusses vendor claims that Sepsis ImmunoScore® can support earlier or more accurate diagnosis and describes product interpretability features. - Media coverage (major consumer and trade outlets) has noted the product's FDA authorization and novel approach; such coverage is not an implementation case study and should not replace localized validation. - Roche/navify listings describe distribution of the algorithm through the navify Algorithm Suite and reference cloud connectivity requirements for that channel.

04Best fit

Company sizes

Best fit appears to be health systems and hospitals that can support integration, clinical governance, and change management, typically mid-to-large hospitals and academic medical centers (generally larger bed counts) with substantial ED/ICU volume.

Industries and verticals

Acute care hospitals
Academic medical centers
Hospital networks participating in multicenter research or clinical trial networks

Roles and personas

Decision makers
- CMIO
- CMO / Chief Quality Officer / Patient Safety
- ICU/ED clinical leadership
- Laboratory leadership (if biomarker testing and marketplace distribution channels are involved)
- IT / Security leadership
End users
- ED physicians, intensivists, hospitalists
- Rapid response teams
- Nursing leadership involved in sepsis pathways

Pain points and challenges the product addresses

Support for earlier identification of sepsis risk or near-term deterioration potential
Tools to reduce missed sepsis diagnoses and increase clinician confidence in treatment decisions (vendor-claimed; should be validated locally)
Potential contribution to quality improvement initiatives and operational metrics, contingent on local implementation and measurement

Qualification criteria: what makes a GOOD fit

High sepsis volume and an institutional priority to improve sepsis detection and timeliness
Ability to measure required inputs reliably and with appropriate turnaround time
Leadership commitment to protocol and workflow design (rather than expecting a plug-and-play solution)
Capacity for regulated SaMD governance and monitoring

05The pitch

What the product does (core value proposition in objective terms)

- Prenosis is a healthcare AI/ML company focused on biology-informed clinical decision support in acute/critical care. - Its flagship product is Sepsis ImmunoScore®, an FDA De Novo–authorized AI/ML Software as a Medical Device (SaMD) intended to aid in risk assessment for presence of or progression to sepsis within 24 hours using a multi-parameter input set (biomarkers + clinical data). Vendor materials state the tool is intended to be used alongside other clinical assessments rather than as an automated alerting system. - Prenosis describes Immunix™ as the underlying precision medicine platform/dataset used to develop algorithms such as Sepsis ImmunoScore®.

Target market and market positioning

- Target customers appear to be U.S. hospitals and health systems (ED, ICU, inpatient) and potentially academic medical centers. - Positioning points in public materials include: - Emphasis on combining biology (biomarkers) with clinical data rather than relying solely on symptom-pattern-only alerts - FDA De Novo authorization as a regulatory distinction compared with many non-FDA-reviewed sepsis early warning systems - Claims about interpretability and human factors intended to support clinician trust

Get a comprehensive analysis of Prenosis including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →